GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Beneish M-Score

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Beneish M-Score

: -3.02 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chugai Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

CHGCF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.02   Med: -2.38   Max: -1.74
Current: -3.02

During the past 13 years, the highest Beneish M-Score of Chugai Pharmaceutical Co was -1.74. The lowest was -3.02. And the median was -2.38.


Chugai Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Chugai Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -2.18 -2.11 -1.74 -3.02

Chugai Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -2.37 -2.08 -1.98 -3.02

Competitive Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Beneish M-Score falls into.



Chugai Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chugai Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7123+0.528 * 0.997+0.404 * 0.9599+0.892 * 0.8185+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2757+4.679 * -0.04691-0.327 * 0.6581
=-3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2,215 Mil.
Revenue was 1901.717 + 1744.374 + 1891.77 + 2336.001 = $7,874 Mil.
Gross Profit was 1262.329 + 1215.07 + 1243.339 + 1203.844 = $4,925 Mil.
Total Current Assets was $9,490 Mil.
Total Assets was $13,422 Mil.
Property, Plant and Equipment(Net PPE) was $2,922 Mil.
Depreciation, Depletion and Amortization(DDA) was $0 Mil.
Selling, General, & Admin. Expense(SGA) was $792 Mil.
Total Current Liabilities was $2,002 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.
Net Income was 633.456 + 524.691 + 588.527 + 549.885 = $2,297 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 862.68 + 211.674 + 896.107 + 955.738 = $2,926 Mil.
Total Receivables was $3,799 Mil.
Revenue was 3250.17 + 1572.287 + 1758.799 + 3038.817 = $9,620 Mil.
Gross Profit was 1672.07 + 1090.057 + 1162.935 + 2073.844 = $5,999 Mil.
Total Current Assets was $9,907 Mil.
Total Assets was $13,859 Mil.
Property, Plant and Equipment(Net PPE) was $2,866 Mil.
Depreciation, Depletion and Amortization(DDA) was $0 Mil.
Selling, General, & Admin. Expense(SGA) was $759 Mil.
Total Current Liabilities was $3,141 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2214.812 / 7873.862) / (3798.975 / 9620.073)
=0.281287 / 0.394901
=0.7123

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5998.906 / 9620.073) / (4924.582 / 7873.862)
=0.623582 / 0.625434
=0.997

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9490.289 + 2921.91) / 13422.19) / (1 - (9906.526 + 2865.89) / 13858.806)
=0.075248 / 0.07839
=0.9599

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7873.862 / 9620.073
=0.8185

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2865.89)) / (0 / (0 + 2921.91))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(792.462 / 7873.862) / (758.941 / 9620.073)
=0.100645 / 0.078891
=1.2757

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 2001.764) / 13422.19) / ((0 + 3140.723) / 13858.806)
=0.149138 / 0.226623
=0.6581

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2296.559 - 0 - 2926.199) / 13422.19
=-0.04691

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chugai Pharmaceutical Co has a M-score of -3.08 suggests that the company is unlikely to be a manipulator.


Chugai Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines